SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Frank Haims who wrote (190)7/6/1997 11:37:00 PM
From: Ed Ajootian   of 10280
 
Frank,

The first Phase II study of Oxybutynin was scheduled to be completed
before midyear, according to the UBS research report on SEPR which was
put out in Oct.

I bet that SEPR has finished the study but purposely waited until the
NDA got filed before putting anything out on Oxy, so as not to steal
levalbuterol's thunder.

BTW, the press coverage of the NDA filing was horrid. Not a peep even
in SEPR's hometown paper, the Boston Globe! Also, I never saw the Dow
wires pick up the story. Did anyone else?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News